India has introduced a major advancement in cancer treatment with the launch of a new seven-minute cancer injection designed for lung cancer patients. The treatment, called Tecentriq, has been launched by Roche Pharma India and is expected to make cancer care faster and more convenient for patients.
The injection is mainly meant for people suffering from non-small cell lung cancer (NSCLC), which is the most common form of lung cancer in India. Unlike traditional immunotherapy treatments that require intravenous (IV) infusions lasting several hours in hospitals, this new method is given under the skin and takes only about seven minutes.
The medicine uses a drug called atezolizumab, which works by blocking a protein known as PD-L1. Cancer cells often use this protein to hide from the body’s immune system. Once blocked, the immune system becomes better at identifying and attacking cancer cells.
Doctors believe this new treatment can significantly improve patient comfort. Cancer patients often spend long hours in hospitals during therapy sessions, leading to physical and mental exhaustion. A shorter treatment process could especially benefit elderly patients and those travelling from distant areas for treatment.
Another important advantage is reduced hospital crowding and improved efficiency in cancer care centres. Experts say the shorter procedure may also encourage better treatment compliance among patients.
However, the launch has also sparked discussions about affordability. Each dose of the injection costs approximately Rs 3.7 lakh, and many patients may require around six doses during treatment. This means the overall cost can run into several lakhs of rupees, making it difficult for many families to afford.
To support patients financially, Roche has introduced a patient assistance programme called “Blue Tree.” The treatment has also been included under the Central Government Health Scheme (CGHS), which may help some eligible patients receive reimbursement support.
Medical experts see this development as an important step in India’s growing focus on advanced cancer therapies and immunotherapy. While affordability remains a challenge, the faster treatment process and improved patient experience could greatly improve the quality of life for many cancer patients across the country.
